Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyViva Health Evenity Coverage & Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0455

    Evenity (romosozumab-aqqg) (Subcutaneous) — Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0455 alerts

    Get alerted when Policy IC-0455 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, eligibility, and billing/coding for Evenity (romosozumab-aqqg) for treatment of osteoporosis, primarily in postmenopausal women, for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyEvenity (romosozumab-aqqg) (Subcutaneous) — Coverage Criteria
    Policy CodePolicy IC-0455
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization; initial approvals valid for 12 months and may not be renewed.
    SourceLink
    12 monthsInitial PA duration
    12Max monthly doses
    210Monthly HCPCS units
    J3111Billing code
    ≥18Min age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    N/AMedicare Part B codes

    Coverage Criteria for Evenity (romosozumab-aqqg)

    Initial Therapy — Postmenopausal Osteoporosis

    Covered when ALL of the following are met

    Age and supplementation: Member is at least 18 years of age; Member is receiving calcium and Vitamin D supplementation if dietary intake is inadequate; and Member does NOT have any FDA-labeled contraindications to the requested agent (e.g., hypocalcemia, known hypersensitivity to Evenity)
    Cardiovascular safety: Member has not had a myocardial infarction or stroke within the preceding year

    In members with other cardiovascular disease and/or risk factors, consider whether benefits of therapy outweigh the risks

    Concomitant therapy restriction: Will not be used in combination with bisphosphonates, denosumab, or parathyroid hormone analogs/related peptides
    Osteoporosis diagnosis and fracture risk: Member must be at high risk for fracture AND have a documented diagnosis of osteoporosis by one or more of: DXA T-score ≤ -2.5 at lumbar spine, femoral neck, total hip, or forearm (33% radius); OR history of fragility fracture to the hip or spine regardless of T-score; OR DXA T-score between -1.0 and -2.5 at the specified sites with either history of proximal humerus/pelvis/distal forearm fracture OR FRAX 10-year probability for major fracture ≥ 20% or hip fracture ≥ 3%

    Specific sites include lumbar spine, femoral neck, total hip, or forearm (33% radius)

    Prior therapy bisphosphonates: Either documented treatment failure or ineffective response to a minimum 12-month trial of bisphosphonates (oral or IV) OR documented contraindication or intolerance to BOTH oral and IV bisphosphonates12 months

    Members with very high risk are not subject to prior trial requirements

    Prior therapy RANKL-blocking agents: Either documented treatment failure or ineffective response to a minimum 12-month trial of RANKL-blocking agents (e.g., denosumab) OR documented contraindication or intolerance to RANKL-blocking agents12 months

    Members with very high risk are not subject to prior trial requirements

    Renewal Therapy — Renewal covered when ALL of the following are met

    Renewal covered when ALL of the following are met

    Duration of authorization has not been exceeded (refer to Section I). Initial authorization is valid for 12 months and may NOT be renewed.

    Coverage is excluded when the member has documented pre-existing hypocalcemia or documented hypersensitivity to romosozumab or its excipients. Evenity will not be used concurrently with bisphosphonates, denosumab, or parathyroid hormone analogs/related peptides. Requests may also be denied for members with FDA‑labeled contraindications or recent cardiovascular events as specified in policy (see cardiovascular safety considerations).

    Providers must ensure documentation of these exclusions is present in the medical record before authorization is approved, since these contraindications and concurrent‑use restrictions are explicit criteria for denial.

    Medicare Part B Covered Diagnosis Codes: N/A. No additional Medicare‑specific diagnosis codes are listed for Evenity in Appendix 3 of this policy; providers billing Medicare should follow applicable NCDs, LCDs, and LCAs as instructed by CMS and the member’s Medicare Administrative Contractor.

    Continuation of Evenity beyond the prescribed treatment course is not covered. Initial prior authorization is valid for 12 months (365 days) and may NOT be renewed; therefore continuation beyond 12 monthly doses will not be authorized.

    Prior authorization requests should reflect the maximum authorized duration and number of doses; renewal requests for additional months or doses beyond the initial 12‑month authorization will be denied per policy.

    Billing, HCPCS, NDCs, and Diagnosis Codes

    HCPCS CodeHCPCS
    J3111Injection, romosozumab-aqqg, 1 mg; 1 billable unit = 1 mg
    NDCNDC
    55513-0880-xxEvenity 105 mg/1.17 mL single-use plastic prefilled syringe (carton of two)
    55513-0998-xxEvenity 105 mg/1.17 mL single-use glass prefilled syringe (carton of two)
    55513-0509-xxEvenity 105 mg/1.17 mL single-use glass prefilled syringe with automatic needle guard (carton of two)
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    M80.00XA-M80.08XSAge-related osteoporosis with current pathological fracture
    M81.0Age-related osteoporosis without current pathological fracture
    Covered ICD-10 CodesICD-10Covered
    M80.00XA-M80.08XSAge-related osteoporosis with current pathological fracture
    M81.0Age-related osteoporosis without current pathological fracture
    Medicare Part B Covered Diagnosis CodesICD-10
    No codes listed
    DXA T-score — diagnostic thresholds for coverage
    DXA T-score thresholdT-score by DXA of ≤ -2.5 at lumbar spine, femoral neck, total hip, or forearm (33% radius)
    Low bone mass with additional riskT-score by DXA between -1.0 and -2.5 at specified sites when accompanied by history of proximal humerus/pelvis/distal forearm fracture or FRAX meeting thresholds
    Fragility fracture regardless of T-scoreHistory of fragility fracture to the hip or spine qualifies regardless of T-score
    FRAX 10-year probability — fracture risk thresholds referenced
    Primary FRAX thresholds for coverageFRAX 10-year probability for major fracture ≥ 20% or hip fracture ≥ 3%

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization validity

    Prior authorization is required for Evenity. Initial prior authorizations are valid for 12 months (365 days) and may NOT be renewed; continuation beyond 12 monthly doses is not covered.

    • Initial authorization: 12 months (365 days)
    • Renewal: prior authorization may NOT be renewed — continuation beyond 12 doses is not covered
    Prior Authorization

    Prior authorization and Medicare compliance

    For non‑Medicare members, coverage determinations follow this policy. For Medicare Part B claims, providers must comply with applicable Medicare resources — the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15 §50, and any relevant NCDs, LCDs, or LCAs available via the CMS coverage database; failure to follow applicable NCDs/LCDs/LCAs may affect payment/coverage.

    • Non‑Medicare determinations follow this policy text
    • Medicare Part B: follow Medicare Benefit Policy Manual and any applicable NCDs/LCDs/LCAs via https://www.cms.gov/medicare-coverage-database/search.aspx

    Definitions and Dosing

    Dose — 210 mg administered as two 105 mg injections monthly for up to 12 doses
    Dose regimen210 mg administered subcutaneously as two separate 105 mg injections by a health care provider every month
    Treatment course lengthGiven monthly for a total of 12 monthly doses (maximum)
    Clinical noteAnabolic effect of Evenity wanes after 12 monthly doses; duration should not exceed 12 months
    Very high risk for fracture — criteria that define very high risk
    Recent fractureFracture within the last 12 months (recent fracture)
    Fractures while on therapy or multiple fracturesFractures occurring while on osteoporosis therapy or multiple fractures

    Background

    Evenity (romosozumab‑aqqg) is administered as a monthly subcutaneous regimen consisting of 210 mg per month delivered as two 105 mg injections given by a healthcare provider. The treatment course is limited to a maximum of 12 monthly doses because the anabolic effect wanes after 12 months and the policy does not permit continuation beyond that duration.

    Therapy should be given with appropriate calcium and vitamin D supplementation when dietary intake is inadequate, and providers must confirm the member meets diagnostic and risk criteria (e.g., osteoporosis by DXA or fragility fracture history) prior to initiating the monthly injections.

    Policy Summary
    PayerViva Health
    PolicyEvenity (romosozumab-aqqg) (Subcutaneous) — Coverage Criteria
    Policy CodePolicy IC-0455
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization; initial approvals valid for 12 months and may not be renewed.
    SourceLink
    On This Page
    Coverage Criteria for Evenity (romosozumab-aqqg)Billing, HCPCS, NDCs, and Diagnosis CodesPrior Authorization, Documentation, and Provider RequirementsDefinitions and DosingBackground
    Very high FRAX thresholds (waives prior trials)FRAX major osteoporotic fracture > 30% or hip fracture > 4.5% (defines very high risk)
    Use with DXA low bone massT-score between -1.0 and -2.5 may meet criteria when accompanied by FRAX ≥20% major or ≥3% hip
    Step Therapy

    Step therapy / prior agent trials

    Prior therapy requirements generally require documented trials with failure or intolerance to specified agents unless the member is very high risk. Documented treatment failure or ineffective response (minimum 12-month trial) to both bisphosphonates (oral or IV) and to RANKL‑blocking agents (e.g., denosumab) — or documented contraindication/intolerance to those agents — must be provided, unless member meets 'very high risk' criteria.

    • Minimum 12-month trial and documented treatment failure or ineffective response for bisphosphonates (oral or IV) OR documented contraindication/intolerance to BOTH oral and IV bisphosphonates
    • Minimum 12-month trial and documented treatment failure or ineffective response for RANKL‑blocking agents (e.g., denosumab) OR documented contraindication/intolerance to RANKL‑blocking agents
    • Prior trial requirements may be waived for members with very high fracture risk (see policy for definitions)
    Note
    Documentation Required

    Clinical documentation of diagnosis, risk, and prior therapy

    Provide all clinical documentation that supports the requested therapy: diagnostic evidence of osteoporosis, fracture risk assessment, and prior therapy records. Include DXA T‑score reports, history of fragility fracture documentation, and FRAX or equivalent fracture‑risk calculations; and records showing prior therapy trials, durations (e.g., 12 months), and outcomes or documented contraindications/intolerances.

    • DXA T-score at lumbar spine, femoral neck, total hip, or 33% radius when applicable (e.g., ≤ -2.5 or -1.0 to -2.5 with additional criteria)
    • History of fragility fracture to hip or spine regardless of T‑score
    • FRAX 10‑year probability when used (policy specifies thresholds)
    • Documentation of prior therapy trials including duration (minimum 12 months), response/failure, or documented contraindication/intolerance
    Billing Rule

    Billing and coding documentation

    Include coding and billing details with the prior authorization and on claims. Use HCPCS code J3111 (Injection, romosozumab-aqqg, 1 mg) and the applicable Evenity NDCs for the supplied prefilled syringes when billing.

    • HCPCS: J3111 — Injection, romosozumab-aqqg, 1 mg (1 billable unit = 1 mg)
    • NDCs: 55513-0880-xx; 55513-0998-xx; 55513-0509-xx (Evenity 105 mg prefilled syringes, carton of two)
    Documentation Required

    Documented diagnosis must match covered ICD‑10 codes

    Ensure the documented diagnosis on the prior authorization and claim matches one of the covered ICD‑10 codes listed in Appendix 1. Accepted codes include the age‑related osteoporosis ranges provided by the policy.

    • Appendix 1 covered ICD‑10 codes: M80.00XA–M80.08XS (age‑related osteoporosis with current pathological fracture) and M81.0 (age‑related osteoporosis without current pathological fracture)
    Denial Risk

    Contraindications and recent MI/stroke — denial risk

    Requests will be denied if the member has FDA‑labeled contraindications or recent cardiovascular events. Do not proceed if there is documented pre‑existing hypocalcemia, known hypersensitivity to Evenity or its excipients, or a myocardial infarction or stroke within the preceding year.

    • FDA‑labeled contraindications example: documented hypocalcemia or hypersensitivity to Evenity/excipients
    • Recent MI or stroke within the prior year — authorization may be denied
    Denial Risk

    Failure to meet diagnostic or prior‑therapy requirements — denial risk

    Authorization may be denied if diagnostic criteria or prior therapy requirements are not met. Specifically, if the member does not meet osteoporosis diagnostic criteria or is not at high risk for fracture and has not had the required trials of bisphosphonates and RANKL‑blocking agents (or documented contraindications/intolerances), coverage may be denied unless the member is 'very high risk.'

    • Denial risk when diagnostic criteria (DXA, fragility fracture, or FRAX thresholds) are not met
    • Denial risk when prior trials of bisphosphonates and/or RANKL‑blocking agents are not documented and member is not very high risk
    Note

    Medicare vs non‑Medicare determinations — provider action

    For Medicare patients, follow Medicare-specific coverage and claims guidance. Non‑Medicare determinations should follow this policy, but Medicare Part B coverage and payment are subject to the Medicare Benefit Policy Manual and applicable NCDs/LCDs/LCAs; noncompliance with those Medicare directives may result in denial or payment issues.

    • Non‑Medicare: apply this policy for coverage determinations
    • Medicare Part B: comply with Medicare Benefit Policy Manual (Pub.100-2), Chapter 15 §50 and any applicable NCDs/LCDs/LCAs
    Severe low T-score or high FRAXT-score < -3.0 or very high FRAX probability (major > 30% or hip > 4.5%)
    High fall/injurious fall risk and drug-related fracturesHigh fall risk/history of injurious falls or fractures while on drugs causing skeletal harm
    Age-related osteoporosis with current pathological fracture — ICD-10 range referenced
    ICD-10 rangeM80.00XA - M80.08XS
    DescriptionAge-related osteoporosis with current pathological fracture
    Use in documentationIncluded in Appendix 1 as covered diagnosis codes for members with current pathological fracture
    Age-related osteoporosis without current pathological fracture — ICD-10 code M81.0
    ICD-10 codeM81.0
    DescriptionAge-related osteoporosis without current pathological fracture
    Appendix referenceListed in Appendix 1 as a covered diagnosis code